|
|
|
|
|
Valsartan
drug data and news
Valsartan drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Valsartan | ||
| Brand Names/Synonyms | Diovan; Diovan Hct; Valsarran; Valsartan; Valsartan [Usan:Inn] | ||
| Indication | For the treatment of hypertension | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Valsartan, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Unlike the angiotensin receptor antagonist losartan, Valsartan does not have an active metabolite or possess uricosuric effects. | ||
| Mechanism Of Action | Valsartan competes with angiotensin II for binding at the AT1 receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance. | ||
| Valsartan News (When available) |
Novartis-tests show new blood pressure drugs work 17 May 2006 Accepted for Review By the FDA As a New Therapy Option for High ... May 9, 2006 Novartis set to trumpet new blood pressure drugs May 12, 2006 FDA OKs higher dose of Novartis' Diovan May 3, 2006 US Submission of Exforge(R) Accepted for Review by the FDA as a ... Apr 26, 2006 (PZ) Novartis Delivers Strong Start to 2006 in First Quarter with ... Apr 24, 2006 Novartis says blood pressure drug Exforge accepted for review by ... Apr 26, 2006 (PRN) - Price Legacy Corporation Declares Series 1 Preferred Stock ... May 1, 2006 Novartis OK'd on higher-dose Diovan May 1, 2006 US Submission of Exforge Accepted for Review by the FDA as a New ... Apr 27, 2006 US Submission of Exforge(R) Accepted for Review by the FDA as a ... Apr 26, 2006 US Submission of Exforge(R) Accepted for Review By the FDA as a ... Apr 27, 2006 US submission of Exforge® accepted for review by the FDA as a new Apr 27, 2006 US Submission of Exforge Accepted for Review by the FDA as a New ... Apr 27, 2006 Novartis' blood pressure drug approved at higher doses May 3, 2006 Novartis files 2-in-1 blood pressure pill in US Apr 26, 2006 Novartis seeks FDA approval for blood pressure drug Apr 28, 2006 First Quarter Report 2006: Schwarz Pharma with a Good Start Apr 25, 2006 | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Antihypertensive Agents; Angiotensin II Receptor Antagonists; ATC:C09CA03 | ||
| Absorption | Not Available | ||
| Interactions |
-->Interactions for Valsartan: No clinically significant pharmacokinetic interactions were observed when valsartan was coadministered with amlodipine, atenolol, cimetidine, digoxin, furosemide, glyburide, hydrochlorothiazide, or indomethacin. The valsartan-atenolol combination was more antihypertensive than either component, but it did not lower the heart rate more than atenolol alone. Coadministration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin. CYP 450 Interactions: The enzyme(s) responsible for valsartan metabolism have not been identified but do not seem to be CYP 450 isozymes. The inhibitory or induction potential of valsartan on CYP 450 is also unknown. As with other drugs that block angiotensin II or its effects, concomitant use of potassium sparing diuretics (e.g. spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]-butanoicacid | ||
| Chemical Formula | C24H29N5O3 | ||
| Molecular Weight | 435.519 g/mol | ||
| Smiles String | CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)C(C(C)C)C(=O)O | ||
| Melting Point | 116-117°C | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 5.159 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 6 hours | ||
| Protein Binding [%] | 95% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Valsartan.html http://www.rxlist.com/cgi/generic/valsartan.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00133 | ||
| CAS Registry Number | 137862-53-4 | ||
| KEGG Compound ID | C07186 | ||
| PubChem ID | SID:197083 | ||
| PharmGKB ID | PA451848 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2244781 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |